The duplex scanner has also been used to study the problems are also present. The aim of this study was to evaluate the effect of topical timolol maleate 0.5%
80w velocity may be due to a vasodilatory effect of timolol. The results are presented and discussed.
Timolol maleate is a topical medication extensively used in ophthalmology to lower the intraocular pressure (lOP) in patients with glaucoma. 1 -5 It is a non-selective beta-adrenergic receptor blocking agent, the hypotensive effect of which has been extensively studied and found to be through a decrease in the rate of aqueous humour formation by the ciliary body. 6 The effect of topical timolol on the retinal circulation has been studied. Grunwald studied the retinal venous circulation as it was inftuenced by topical timolol maleate 0.5% utilising a laser Doppler. He found a significant increase in the venous blood flow in normal volunteers7 and in ocular hypertensives. 8 The blood flow velocity in the central retinal artery (CRA) of normal human problems are also present. The aim of this study was to evaluate the effect of topical timolol maleate 0.5%
on the flow velocity of the CRA in the eyes of patients with diabetes or peripheral and/or cerebro vascular disease. We present our results using the duplex scanner for the flow measurements.
MATERIALS AND METHODS
In this study we used a high-resolution ATL The nature of the experiment was fully explained to each of the patients and informed consent was obtained before beginning. The patient was exam ined while lying on his or her back on the examining table. Our technique to measure the blood flow velocity of the CRA has been described pre viously. lO · 11 One eye was selected from each of the patients and the peak systolic flow velocity (PSFV) and end-diastolic flow velocity (EDFV) of the CRA as it exits from the optic nerve head were measured. The carotid flow velocity was also recorded on the same side as the eye selected to be studied in our normals, to ensure that haemodynamically significant lesions were not present that could alter the ocular measurements. In the case of patients with diabetes or vascular disease, we also took measurements of the flow of the carotid and peripheral vessels to evaluate the presence and extent of their disease. Following the initial eye measurements a drop of timolol maleate 0.5% was instilled in the eye to be studied, followed by a second drop 5 minutes later. After 30-45 minutes the PSFV and the EDFV in the CRA were again measured and recorded in that eye. The diastolic component [D.Comp. = EDFV/(PSFVI 100)] was calculated for the flow velocity before and after topical timolol.
The Mann-Whitney U-test was used for statistical analysis.
The patients were divided into four groups. The first consisted of our control group of healthy white volunteers. The second group was patients with cerebrovascular or peripheral vascular disease who had a decrease in the blood flow velocity of the CRA. The third group was insulin-dependent diabetic patients who had peripheral diabetic micro angiopathy detected by laser Doppler flowmetry. 12 , 13 The diabetics were further divided into two sub groups according to the blood flow velocity of the CRA: subgroup A had an increase in the flow velocity of the CRA and subgroup B had a decrease in the flow velocity of the CRA. The eye flow studies were done together with the peripheral flow evaluations. In the case of hypertensive patients, there was a washout period in which the patients were off their medication before the study. Patients on cardiovascular medication were also excluded. The pupils of the eyes were not dilated during the flow measurements to avoid any effect the mydriatic drops could have on the retinal blood. After the administration of timolol drops we also monitored the peripheral microcirculation of all the patients to evaluate possible systemic microcirculatory effects of timolol. Patients were excluded if they had severe cardiac disease, if there was renal impairment, if a neoplasm was present or if they had other major systemic disease.
RESULTS
General information about the three groups is presented in Table I , indicating the number of pa ' tients, their age, blood pressure and the duration of their disease.
The first group consisted of 12 healthy white volunteers. There was no history of ocular or systemic disease and all had normal eye examina tions with a best refracted visual acuity of 20/20 (6/6) or better. The intraocular pressure was 21 mmHg or less and the anterior segment and fundus examina tions were normal. None were known diabetics, none had known circulatory problems and none were taking systemic or ocular medication. The mean age was 45.7 years (SD 9). In these patients the mean brachial systolic pressure was 118.7 mmHg (SD 13) and the mean diastolic pressure was 71.4 mmHg (SD 9). After the administration of topical timolol maleate 0.5% there was an increase in the blood flow velocity of the CRA in all the eyes. The PSFV increased from 22.1 cmls (SD 4) to 26.5 cmls (SD 6) (p<0.0l). The EDFV increased from 10.3 cmls (SD 3) to 13.5 cmls (SD 4) (p<0.05). The D.Comp. increased also, from 46.60% to 58.49% (p<0.05) ( Table II) .
The second group consisted of 23 patients with either central or peripheral vascular problems as documented by us with duplex scanning andlor CT scanning. The ocular examinations were normal with intraocular pressures of 21 mmHg or less. The patients with previous ocular surgery or ocular disease such as glaucoma or uveitis were excluded. None were taking ocular medication. These patients were seen in our vascular centres and all had a decrease in the flow velocity of the CRA when compared with that in our normals. There was an increase in the flow velocity after topical timolol maleate 0.5% but it was less than that seen in the normals. Their mean age was 59.7 years (SD 9) and there was a moderate increase in the brachial blood pressure with a mean of 146.7/94.6 mmHg (SD 16 and 9). The PSFV was 16.8 cmls (SD 7), significantly slower than that in the normals (p<0.01), and it increased after topical timolol to 20.7 cmls (SD 9) (p<0.01). The EDFV was 7.1 cmls (SD 6), again significantly reduced when compared with that of the normals (p<0.05), and increased after topical timolol to 10.3 cmls (SD 6) (p<0.05). The D.Comp. before timolol of 42.26%, which was significantly reduced when compared with that of the normals (p<0.05%), increased after topical timolol to 49.75% (p<0.01) (Table III) . Three other vascular patients were seen by us who had no increase in the flow of the CRA after topical timolol. All 3 had an internal carotid occlusion.
The third group consisted of 43 insulin-dependent diabetics with a mean age of 56.6 years (SD 9). These patients had intraocular pressures of 21 mmHg or less and none had glaucoma or previous ocular surgery. Their fundus examinations were either normal or showed mild background diabetic retino pathy (BDR). Patients with diabetic macular oedema (DMO), preproliferative diabetic retinopathy or proliferative diabetic retinopathy (PDR) were excluded. These patients had peripheral diabetic micro angiopathy as detected by laser Doppler flowmetry and could be divided into two subgroups according to their blood flow characteristics. Sub group A consisted of 23 patients with an increase in the flow velocity of the CRA when compared with the flow in normals. Subgroup B consisted of 20 patients who had a decrease in the flow velocity of the CRA with both the systolic and diastolic phases of flow being decreased. The patients in subgroup A were diabetics of moderate duration with a mean disease duration of 6.7 years (SD 5) and with intermediate phases of microvascular complications. They had significantly altered laser Doppler para meters of the peripheral and distal (foot) circulation with an increased resting blood flow (RBF) in the skin of the feet and a decreased venoarteriolar reflex. 12.13 These patients were without severe neuropathy as shown by electromyography and without large vessel disease. The patients in subgroup B were diabetics of longer standing with a mean disease duration of 13.5 years (SD 7) who had more severe and long-standing micro angiopathy with more severe microvascular peripheral altera tions on laser Doppler flowmetry. They all had a decrease in the blood pressure (Doppler ultra sonography) in the skin of the feet. These diabetics with longer-standing disease tended to have claudi cation (12 of 20), large vessel disease and skin ulceration (7 of 20) in addition to the marked alterations in their microcirculatory skin flUX. 14 These characteristics of the two subgroups paral leled the flow characteristics that were measured in the eye. In subgroup A the flow velocity of the CRA was significantly increased when compared with that of normals. The PSFV was 29.7 cmls (SD 11), significantly higher than that in the normals (p<0.01), and the change after topical timolol was not significant (Table IV) . The EDFV was 18.7 cmls (SD 9), significantly increased when compared with that of the normals (p<0.01), and the change after topical timolol was also not significant (Table IV) . The change in the D.Comp. for this subgroup was also not significant. In subgroup B the flow velocity of the CRA was significantly decreased when compared with that of the normals. The PSFV was 14.6 cmls (SD 4), significantly decreased when compared with that of the normals (p<0.01), and (Table IV) . In this group the D.Comp. was less than that in the normals but did increase after timolol (Table IV) Clinical studies will be needed to evaluate the effect this increased flow velocity may have on the vision in normals, diabetics and vascular patients, as well as the effect it may have on diabetic retinopathy. In particular it will be important to know how DMO and PDR are affected by this increased flow velocity.
